FDA Approves Tzield to Slow Type 1 Diabetes Progression in Children

On June 13, 2026, the FDA granted accelerated approval to Tzield (teplizumab-mzwv), marking the first disease-modifying therapy approved to slow the decline of insulin production in children with stage 3 type 1 diabetes. The approval applies to children ages 8–17 who have been recently diagnosed.

Stage 3 type 1 diabetes is when the autoimmune attack on insulin-producing beta cells is actively progressing and patients often begin experiencing noticeable symptoms. Each year, approximately 64,000 people are diagnosed with type 1 diabetes in the United States.

Tzield's approval was supported by data from the PROTECT phase 3 clinical trial (NCT03875729). The primary measure of success was how well the drug preserved beta cell function—specifically, by measuring C-peptide levels using a four-hour mixed-meal tolerance test.

Results showed that Tzield significantly slowed the decrease in mean C-peptide levels compared to placebo, with a difference in least-squares means of 0.13 pmol/mL (95% confidence interval: 0.09–0.17). This indicates the drug preserved more of the body's own insulin production over time.

Like all medications, Tzield carries both common and serious side effects. The most frequently reported adverse reactions include lymphopenia (low white blood cell count), vomiting, rash, leukopenia (low white blood cells), diarrhea, neutropenia (low neutrophil count), increased liver enzymes, and headache.

More serious events have also been reported, including cytokine release syndrome and life-threatening viral reactivation. People who are already immunocompromised face elevated risk for viral reactivation. These risks are important to discuss with a healthcare provider when considering whether Tzield is appropriate.

Tzield represents the first therapeutic option designed to modify the course of stage 3 type 1 diabetes by targeting its autoimmune nature. However, it is important to understand that Tzield slows disease progression—it does not stop or reverse type 1 diabetes.

The accelerated approval pathway means the FDA determined there is compelling evidence of benefit, though ongoing monitoring will continue. This approval provides families and healthcare providers with a new tool during a critical window when children are newly diagnosed.

Origin: finance.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.